Zimmer Biomet has opportunity to show turnaround progress, says Cowen

Cowen analyst Joshua Jennings noted supply constraints have weighed on the financials of Zimmer Biomet, but it looks to be nearing a resolution point. The analyst said management expressed cautious optimism toward Q3, citing supply recovery efforts and new product launches as positive tailwinds. Jennings maintained his Market Perform rating and $130 price target on Zimmer Biomet shares.
https://thefly.com/landingPageNews.php?id=2791885